Oncotarget

Research Papers:

CFIm25 inhibits hepatocellular carcinoma metastasis by suppressing the p38 and JNK/c-Jun signaling pathways

Yunwu Wang _, Yu Xu, Wei Yan, Ping Han, Jingmei Liu, Jin Gong, Dongxiao Li, Xiangming Ding, Han Wang, Zhuoying Lin, Dean Tian and Jiazhi Liao

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:11783-11793. https://doi.org/10.18632/oncotarget.24364

Metrics: PDF 1351 views  |   HTML 1836 views  |   ?  


Abstract

Yunwu Wang1, Yu Xu1, Wei Yan1, Ping Han1, Jingmei Liu1, Jin Gong1, Dongxiao Li1, Xiangming Ding1, Han Wang1, Zhuoying Lin1, Dean Tian1 and Jiazhi Liao1

1Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Correspondence to:

Dean Tian, email: [email protected]

Jiazhi Liao, email: [email protected]

Keywords: hepatocellular carcinoma; CFIm25; alternative polyadenylation; EMT; metastasis

Received: August 05, 2017     Accepted: December 05, 2017     Published: January 31, 2018

ABSTRACT

Alternative polyadenylation (APA), a post-transcriptional modification, has been implicated in many diseases, but especially in tumor proliferation. CFIm25, the 25 kDa subunit of human cleavage factor Im (CFIm), is a key factor in APA. We show that CFIm25 expression is reduced in human hepatocellular carcinoma (HCC), and its expression correlates with metastasis. Kaplan-Meier analysis indicated that CFIm25 is related to overall survival in HCC. Moreover, CFIm25 expression is negatively related to the metastatic potential of HCC cell lines. CFIm25 knockdown promotes cell invasion and migration in vitro, while overexpression of CFIm25 inhibits cell invasion and migration in vitro and inhibits intrahepatic and lung metastasis in vivo. Additional studies showed that CFIm25 disrupts epithelial-mesenchymal transition by increasing E-cadherin, that it inhibits HCC cell migration and invasion by blocking the p38 and JNK/c-Jun signaling pathways, and that CFIm25 knockdown increases the transcriptional activity of activating protein-1 (AP-1). These findings indicate that therapy directed at increasing CFIm25 expression is a potential HCC treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24364